header image

Brain Modulation Laboratory

The Brain Modulation Laboratory, directed by R. Mark Richardson, MD, PhD, is a human systems neuroscience lab that studies brain electrophysiology, cognition, imaging, and histopathology in patients undergoing surgery for epilepsy and movement disorders. The overall goal of the lab’s work is to facilitate the optimization of brain modulation therapies and the discovery of novel neurobiological targets, by filling gaps in our understanding of human brain function critical for helping patients.

Major areas of study include:

Basal Ganglia-Cortical Dynamics in Human Behavior
Intraoperatively, task-based, simultaneously recorded cortical ECoG and subcortical MER/LFP data are collected to study interactions between the cortex and basal ganglia that code for specific components of motor action. This work is currently funded by an NINDS U01 through the BRAIN Initiative, as well as an R01 for Collaborative Research in Computational Neuroscience in conjunction with the Movement Disorders Section at Charité-Universitätsmedizin Berlin. The ultimate goal is to inform the development of next generation DBS systems.

Brain Stimulation for Epilepsy
Dr. Richardson’s lab has created a data management and analysis pipeline (BRAINStim: Biophysically Rational Analysis for Individualized Neural Stimulation) to study recordings generated in epilepsy patients implanted with the Responsive Neurostimulation System (RNS), which is generating several high impact findings. In complimentary and longstanding experiments, Dr. Richardson’s lab has studied the effects of chronic stimulation in an NHP with idiopathic epilepsy, implanted with a sensing-enabled DBS device (RC+S). The ultimate goal is to optimize closed-loop brain stimulation for epilepsy.

For more detailed information on the Brain Modulation Laboratory, please visit brainmodulationlab.org.

We are indebted to our epilepsy and movement disorder patients who allow the use of their clinical data to benefit neuroscience and to potentially help future patients.